Metrics as of 10/17/2026, 08:46 AM (Berlin time), refresh in progress.
Xencor Stock
Xencor, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Bassil I. Dahiyat
- Employees
- 260
- Market cap
- $1.7 B
- IPO
- 03/12/2013
Xencor, Inc. is a healthcare company in the biotechnology industry headquartered in Pasadena, US. Established in 1997, the biopharmaceutical firm operates as a clinical-stage entity focused on the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics. These treatments primarily aim…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Xencor stock: price history
1D
-4.8%
1W
-7.2%
1M
-3.6%
6M
+75.0%
YTD
+49.2%
1Y
+52.8%
2Y
+6.2%
5Y
-40.6%
10Y
+12.5%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~22% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Xencor stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Xencor is a clinical-stage biopharmaceutical company specializing in the discovery and engineering of monoclonal antibodies and cytokine therapeutics. The focus is on treating cancer and autoimmune diseases. The business model is primarily based on generating royalties and milestone payments, which is realized through collaborations with partners on established marketed therapies such as Ultomiris and Monjuvi. In addition to the existing revenue stream, the company maintains an extensive pipeline of drug candidates in various clinical development stages for indications including oncology, infectious diseases, and neurodegenerative diseases.
- Revenue model
- Mixed
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
Caris Life Sciences, Inc.DescriptionAsk the agents about Xencor
Analyst assessment of Xencor
PRICE TARGET LOW
US$20.00
CONSENSUS
US$34.40
MEDIAN
US$35.00
PRICE TARGET HIGH
US$46.00
1
STRONG BUY
24
BUY
2
HOLD
1
SELL
0
STRONG SELL
28
TOTAL · Buy
As of: 28/09/2026
Xencor stock metrics
P/E
-10.53
P/B
3.44
EV/EBITDA
-13.91
RETURN ON EQUITY
-4.3%
NET MARGIN
-42.4%
DEBT/EQUITY
0.13
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
73.0%
FLOAT SHARES
54,251,213
AVG. DAILY VOLUME (30D)
1,416,186
Insider transactions (SEC)
GORMAN KEVIN CHARLES
SIMPSON TODD E
RANIERI RICHARD J
Montgomery Alan Bruce
GUSTAFSON KURT A
Institutional holders
Comparable stocks
Frequently asked questions about Xencor stock
What does Xencor do?
Xencor, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Bassil I. Dahiyat, the company employs around 260 people.
The IPO was on 03/12/2013; the stock trades on NASDAQ under the ticker XNCR.
What do analysts say about Xencor stock?
28 analysts rate the stock, the consensus is Buy (as of 28/09/2026).
The average price target is US$34.40, ranging from US$20.00 to US$46.00, with a median of US$35.00.
This is an external assessment, not a statement by Market Jury.
When does Xencor report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 22% stronger than usual.
Does Xencor pay a dividend?
No, Xencor currently does not pay a dividend.
Which stocks are comparable to Xencor?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Xencor stock analyzed?
Clicking "Analyze stock" lets five strategies assess Xencor against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.